SYK
Stryker Corp
$331.45
+1.67 (+0.51%)
At close · Jul 13
Market Cap
$127.06B
Shares
383,360,762
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$25.12B
+11.2%
FY2025
Net Income
$3.25B
+8.5%
FY2025
Gross Margin
63.96%
0pp
FY2025
Operating Margin
19.47%
+3.1pp
FY2025
Diluted EPS
$8.40
+8.2%
FY2025
Operating Cash Flow
$5.04B
+18.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $25.27B | $25.12B | $22.6B | $20.5B | $18.45B | $17.11B | $14.35B | $14.88B | $13.6B | $12.44B | $11.33B | $9.95B | $9.68B | $9.02B | $8.66B | $8.31B | $7.32B | $6.72B | $6.72B | $6B | |
| $9.14B | $9.05B | $8.16B | $7.44B | $6.87B | $6.14B | $5.29B | $5.19B | $4.66B | $4.26B | $3.82B | $3.34B | $3.32B | $3B | $2.78B | $2.81B | $2.29B | $2.18B | $2.13B | $1.87B | |
| $16.13B | $16.07B | $14.44B | $13.06B | $11.58B | $10.97B | $9.06B | $9.7B | $8.94B | $8.18B | $7.5B | $6.6B | $6.36B | $6.02B | $5.88B | $5.5B | $5.03B | $4.54B | $4.59B | $4.14B | |
| — | 63.96% | 63.91% | 63.7% | 62.76% | 64.11% | 63.11% | 65.14% | 65.72% | 65.73% | 66.26% | 66.38% | 65.7% | 66.72% | 67.88% | 66.16% | 68.77% | 67.51% | 68.27% | 68.92% | |
| $1.63B | $1.62B | $1.47B | $1.39B | $1.45B | $1.24B | $984M | $971M | $862M | $787M | $715M | $625M | $614M | $536M | $471M | $462M | $394M | $336M | $367.8M | $375.3M | |
| $8.63B | $8.65B | $7.69B | $7.11B | $6.39B | $6.43B | $5.36B | $5.36B | $5.1B | $4.55B | $4.14B | $3.61B | $3.55B | $3.47B | $3.37B | $3.15B | $2.71B | $2.51B | $2.63B | $2.39B | |
| $745M | $732M | $623M | $635M | $627M | $619M | $472M | $464M | $417M | $371M | $319M | $210M | $188M | $138M | $123M | $122M | $58M | $36M | $40M | $41.4M | |
| $1.61B | $1.57B | $1.43B | $1.34B | $1.28B | $1.27B | $1.08B | $1.04B | $966M | $859M | $752M | $590M | $586M | $511M | $486M | $481M | $410M | $385M | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | $50M | $75M | $76M | — | $67M | $34.9M | $0 | |
| $11.14B | $11.18B | $10.75B | $9.17B | $8.74B | $8.38B | $6.83B | $6.98B | $6.4B | $5.88B | $5.33B | $4.74B | $5.11B | $4.76B | $4.14B | $3.81B | $3.28B | $2.95B | $3.07B | $2.83B | |
| $4.99B | $4.89B | $3.69B | $3.89B | $2.84B | $2.58B | $2.22B | $2.71B | $2.54B | $2.3B | $2.18B | $1.86B | $1.25B | $1.26B | $1.74B | $1.69B | $1.75B | $1.59B | $1.52B | $1.31B | |
| — | 19.47% | 16.33% | 18.97% | 15.4% | 15.1% | 15.49% | 18.23% | 18.65% | 18.46% | 19.21% | 18.71% | 12.88% | 13.92% | 20.11% | 20.3% | 23.92% | 23.71% | 22.61% | 21.79% | |
| $6.59B | $6.46B | $5.12B | $5.23B | $4.12B | $3.86B | $3.3B | $3.76B | $3.5B | $3.16B | $2.93B | $2.45B | $1.83B | $1.77B | $2.23B | $2.17B | $2.16B | $1.98B | — | — | |
| — | $607M | $409M | $363M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $230M | $232M | $212M | $148M | -$158M | -$303M | -$269M | -$151M | -$181M | -$234M | -$254M | -$126M | -$86M | -$44M | -$36M | — | -$22M | $30M | $61.2M | $62.8M | |
| $4.6B | $4.51B | $3.49B | $3.67B | $2.68B | $2.28B | $1.95B | $2.56B | $2.36B | $2.06B | $1.92B | $1.74B | $1.16B | $1.21B | $1.71B | $1.69B | $1.73B | $1.62B | $1.58B | $1.37B | |
| $1.26B | $1.27B | $499M | $508M | $325M | $287M | $355M | $479M | -$1.2B | $1.04B | $274M | $296M | $645M | $206M | $407M | $341M | $456M | $517M | $432.4M | $383.4M | |
| $3.34B | $3.25B | $2.99B | $3.17B | $2.36B | $1.99B | $1.6B | $2.08B | $3.55B | $1.02B | $1.65B | $1.44B | $515M | $1.01B | $1.3B | $1.35B | $1.27B | $1.11B | $1.15B | $1.02B | |
| — | 12.92% | 13.25% | 15.44% | 12.78% | 11.66% | 11.14% | 13.99% | 26.12% | 8.2% | 14.54% | 14.47% | 5.32% | 11.15% | 14.99% | 16.19% | 17.39% | 16.47% | 17.08% | 16.96% | |
| $3.16B | $2.85B | $3.12B | $2.97B | $2.67B | $2.62B | $1.05B | $2.11B | $3.48B | $1.23B | $1.53B | $1.05B | $29M | $1.11B | $1.28B | $1.34B | $1.17B | $1.2B | $1.05B | $1.19B | |
| USD/shares | — | $8.49 | $7.86 | $8.34 | $6.23 | $5.29 | $4.26 | $5.57 | $9.50 | $2.73 | $4.40 | $3.82 | $1.36 | $2.66 | $3.41 | $3.48 | $3.21 | $2.79 | $2.81 | $2.48 |
| USD/shares | — | $8.40 | $7.76 | $8.25 | $6.17 | $5.21 | $4.20 | $5.48 | $9.34 | $2.68 | $4.35 | $3.78 | $1.34 | $2.63 | $3.39 | $3.45 | $3.19 | $2.77 | $2.78 | $2.44 |
| shares | — | 382.2M | 381M | 379.6M | 378.2M | 377M | 375.5M | 374M | 374.1M | 374M | 374.1M | 376.6M | 378.5M | 378.6M | 380.6M | 386.5M | 396.4M | 397.4M | 408.1M | — |
| shares | — | 386.5M | 385.6M | 383.7M | 382.2M | 382.3M | 380.3M | 379.9M | 380.3M | 380.1M | 378.5M | 380.9M | 382.8M | 382.1M | 383M | 389.5M | 399.5M | 399.4M | 413.6M | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2007–FY2025: $4.12B in buybacks, $11.84B in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Medical Devices median 2.41×
EV/EBIT
—
Medical Devices median 21.52×
P/E (TTM)
38.36×
Medical Devices median 27.15×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| MedSurg and Neurotechnology | $15,647,000,000 | $13,518,000,000 | $12,163,000,000 | $10,893,000,000 | $9,538,000,000 | $8,345,000,000 | $8,475,000,000 | — |
| Orthopaedics and Spine | $9,469,000,000 | $9,077,000,000 | $8,335,000,000 | $7,556,000,000 | $7,570,000,000 | $6,006,000,000 | $6,409,000,000 | — |
| Orthopaedics | $9,469,000,000 | $9,077,000,000 | $8,335,000,000 | $7,556,000,000 | — | $4,959,000,000 | $5,252,000,000 | $4,991,000,000 |
| Medsurg | — | — | — | — | — | $6,400,000,000 | $6,492,000,000 | $6,045,000,000 |
| Neurotechnology and Spine | — | — | — | — | — | $2,992,000,000 | $3,140,000,000 | $2,565,000,000 |
| Reconstructive | — | — | — | — | — | $4,959,000,000 | $5,252,000,000 | $4,991,000,000 |
By Geography (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| United States | $19,006,000,000 | $16,943,000,000 | $15,257,000,000 | $13,638,000,000 | $12,321,000,000 | $10,455,000,000 | $10,957,000,000 | $9,848,000,000 |
| Non Us | $6,110,000,000 | $5,652,000,000 | $5,241,000,000 | $4,811,000,000 | $4,787,000,000 | $3,896,000,000 | $3,927,000,000 | $3,753,000,000 |
| EMEA | $3,181,000,000 | $2,897,000,000 | $2,618,000,000 | $2,348,000,000 | $2,299,000,000 | $1,818,000,000 | $1,888,000,000 | $1,793,000,000 |
| Asia Pacific | $2,164,000,000 | $2,020,000,000 | $1,946,000,000 | $1,885,000,000 | $1,973,000,000 | $1,630,000,000 | $1,617,000,000 | $1,532,000,000 |
| Other Foreign Countries | $765,000,000 | $735,000,000 | $677,000,000 | $578,000,000 | $515,000,000 | $448,000,000 | $422,000,000 | $428,000,000 |
By Product & Service (USD)
| Component | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Neuro Cranial Interventional Spine | $413,000,000 | $327,000,000 | $282,000,000 | — |
| Other Orthopedics Enabling Technologies | $152,000,000 | $149,000,000 | $131,000,000 | — |
| Other Med Surg And Neurotechnology | — | $343,000,000 | $302,000,000 | $277,000,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| MedSurg and Neurotechnology | $4,672,000,000 | $4,004,000,000 | $3,470,000,000 | $2,831,000,000 | $2,807,000,000 | $2,414,000,000 | $2,304,000,000 | — |
| Orthopaedics | $2,820,000,000 | $2,591,000,000 | $2,265,000,000 | $2,202,000,000 | — | — | — | — |
| Medsurg | — | — | — | — | — | $1,837,000,000 | $1,642,000,000 | $1,444,000,000 |
| Neurotechnology and Spine | — | — | — | — | — | $647,000,000 | $839,000,000 | $700,000,000 |
| Orthopaedics and Spine | — | — | $2,399,000,000 | $2,296,000,000 | $2,180,000,000 | $1,588,000,000 | $2,084,000,000 | — |
| Reconstructive | — | — | — | — | — | $1,518,000,000 | $1,907,000,000 | $1,804,000,000 |
Operating Margin by Segment (%)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| MedSurg and Neurotechnology | 29.9% | 29.6% | 28.5% | 26% | 29.4% | 28.9% | 27.2% | — |
| Orthopaedics and Spine | — | — | 28.8% | 30.4% | 28.8% | 26.4% | 32.5% | — |
| Orthopaedics | 29.8% | 28.5% | 27.2% | 29.1% | — | — | — | — |
| Medsurg | — | — | — | — | — | 28.7% | 25.3% | 23.9% |
| Neurotechnology and Spine | — | — | — | — | — | 21.6% | 26.7% | 27.3% |
| Reconstructive | — | — | — | — | — | 30.6% | 36.3% | 36.1% |
Key facts
CIK
310764
CUSIP
863667101
13F (30d)
258 filings
211 filers
Visit website
Investor relations